<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971280</url>
  </required_header>
  <id_info>
    <org_study_id>0008-16-RMB</org_study_id>
    <nct_id>NCT02971280</nct_id>
  </id_info>
  <brief_title>Influence of Heavy Metals Exposure on in Vitro Fertilization (IVF) Outcome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exposure to heavy metals may interfere with basic cellular functions, including DNA&#xD;
      synthesis.&#xD;
&#xD;
      The aim of the study is to correlate heavy metals concentration in body fluids of&#xD;
      reproductive importance and IVF outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concentration of heavy metals will be measured in blood, urine, semen fluid and follicular&#xD;
      fluid of IVF patients.&#xD;
&#xD;
      Study group: poor prognosis patients: repeated IVF failure, implantation failure, poor&#xD;
      ovarian response, low sperm quality (according to WHO criteria) Control group: Good prognosis&#xD;
      patients. Normal sperm count. Heavy metals concentrations will be measured using atomic&#xD;
      absorption spectrometer, and will be correlated with IVF outcomes: number of mature oocytes&#xD;
      obtained, fertilizations, embryos quality, and reproductive outcome post embryo transfer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate (&quot;take-home baby&quot;)</measure>
    <time_frame>9 months from embryo transfer</time_frame>
    <description>IVF cycle resulting in pregnancy that ends in a live birth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>1 month from embryo transfer</time_frame>
    <description>Gestational sac(s) seen by ultrasound 1 month after embryo transfer.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fertilization in Vitro</condition>
  <eligibility>
    <study_pop>
      <textblock>
        IVF patients (women and men)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age of female patients: &lt;=39&#xD;
&#xD;
          -  Age of male patients: 18-50&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Alcohol/drug abuse&#xD;
&#xD;
          -  Long-term/chronic medications&#xD;
&#xD;
          -  Severe health/mental problems&#xD;
&#xD;
          -  Dental or other transplants&#xD;
&#xD;
          -  Fragile X mutations&#xD;
&#xD;
          -  Fertility preservation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shahar Kol, MD</last_name>
    <phone>97247773232</phone>
    <email>skol@rambam.health.gov.il</email>
  </overall_contact>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Shahar Kol MD</investigator_full_name>
    <investigator_title>Director IVF Unit, principal investigator, Assistant clinical Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be published in scientific journal. Individual researchers will have access to source data anonymously.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

